Moreover, we conducted a correlation analysis between IRS2 amplification and routine biomarkers (KRAS, NRAS, BRAF, ERBB2, APC, and TP53) in CRC patients (Supplementary Table S10). This evidence concerns the gene KRAS and colorectal carcinoma.